Morgan Stanley cuts Halozyme to Equalweight on valuation
Alpha Vantage · Investing.com Nigeria · · AI-summarised by FinFlash
Morgan Stanley downgraded Halozyme Therapeutics to Equalweight from Overweight, nudging its price target to Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context